Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Hereditary Angioedema Therapeutics Market Forecast: Value Set To Climb From $9.27 Billion To $19.03 Billion
The hereditary angioedema therapeutics market size has expanded considerably in recent years. This market is set to expand from $7.77 billion in 2025 to $9.27 billion in 2026, showing a compound annual growth rate (CAGR) of 19.3%. The factors contributing to its historical growth include limited awareness about hae, a dependence on hospital-based therapy, fewer approved therapeutic options available, a reliance on intravenous administration methods, and low prevalence diagnosis rates.
The hereditary angioedema therapeutics market is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $19.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.7%. This expansion during the forecast period can be linked to several factors, including the increasing development of recombinant C1 esterase inhibitors, the uptake of subcutaneous delivery methods, a rise in the use of prophylactic therapies, the broadening of specialty pharmacy networks, and greater investment in research for rare diseases. Key developments expected within this period involve the evolution of personalized therapies, an increase in orphan drug approvals, ongoing progress in subcutaneous drug delivery systems, the creation of on-demand treatment solutions, and the enlargement of both hospital and retail pharmacy networks.
Get A Free Sample Report With In-Depth Market Insights:
Hereditary Angioedema Therapeutics Market Development Factors: What’s Supporting Demand?
The escalating healthcare expenditure is anticipated to drive the expansion of the hereditary angioedema therapeutics market in the coming years. Healthcare expenditure denotes the overall sum of resources, including financial assets, dedicated to healthcare products and services within a specific timeframe and geographical area. Higher healthcare spending enables enhanced investment in research and development initiatives focused on comprehending the fundamental causes of hereditary angioedema and devising innovative treatment solutions. For example, in June 2025, data from the Centers for Medicare & Medicaid Services (CMS), the US federal agency, indicated that National Health Expenditure (NHE) grew 7.5% to $4.9 trillion in 2023, equivalent to $14,570 per person, and comprised 17.6% of Gross Domestic Product (GDP). Hospital expenditures experienced a 10.4% increase to $1,519.7 billion in 2023, surpassing the 3.2% growth recorded in 2022. Therefore, the rise in healthcare expenditure is propelling the growth of the hereditary angioedema therapeutics market.
Hereditary Angioedema Therapeutics Market Segment Breakdown: Which Categories Lead On Revenue?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-Demand
Hereditary Angioedema Therapeutics Market Transformation Trends: What Innovations Are Driving Change?
Leading companies within the hereditary angioedema (HAE) therapeutics market are engaged in the development of cutting-edge treatments, such as oral plasma kallikrein inhibitors. These innovations aim to optimize patient care and provide effective, immediate solutions for HAE attack relief, thereby enhancing overall patient well-being and life quality. Oral plasma kallikrein inhibitors are orally administered medications designed to suppress the enzyme plasma kallikrein, which assists in managing and reducing the intensity of hereditary angioedema episodes. An example of this progress is KalVista Pharmaceuticals, a US-based biopharmaceutical firm, which in September 2024, obtained a US. Food and Drug Administration New Drug Application for Sebetralstat. This development is intended to offer HAE patients a more user-friendly, non-invasive treatment option, distinct from intravenous or subcutaneous drugs. Such a treatment addresses the increasing need for rapid and efficient oral therapies that can be used immediately upon the onset of a hereditary angioedema attack.
Hereditary Angioedema Therapeutics Market Leading Players And Competitive Positioning
Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.
View The Full Hereditary Angioedema Therapeutics Market Report:
Hereditary Angioedema Therapeutics Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model